Treatment of Hypotension of Prematurity: a randomised trial
- PMID: 40413017
- DOI: 10.1136/archdischild-2024-328253
Treatment of Hypotension of Prematurity: a randomised trial
Abstract
Objective: To evaluate whether a perfusion-based approach (permissive hypotension, PH) for idiopathic low mean arterial blood pressure (MABP) during the first 72 hours after birth in preterm infants without overt sepsis affects neurodevelopmental outcome (NDO) at 24 months of age.
Design: Randomised controlled trial. Outcome assessors were blinded.
Setting: Single centre.
Patients: Infants <30 weeks gestational age (GA) with MABP in mm Hg <GA in weeks during the first 72 hours after birth, without overt signs of sepsis.
Intervention: Random assignment to PH, initiating treatment on signs of low perfusion and/or a MABP 5 mm Hg below their GA in weeks, or standard treatment (ST), initiating treatment when MABP was <GA in weeks.
Main outcome measures: Death, NDO at 24 months, and composite adverse outcome (death or cognitive and/or motor NDO below -1 SD).
Results: 86 infants were included, 57.3% of projected inclusions. Both cognitive NDO (PH-ST mean difference 0.8 (95% CI -5.6 to 7.3)) and motor NDO (mean difference 3.7 (-3.3 to 10.7)) were comparable. The relative risks for death (1.4 (0.6 to 3.7)) and composite adverse outcome (0.8 (0.5 to 1.3)) were comparable. The number of infants with inotropic support (n=19 (42.5%) vs 7 (15.2%), p=0.004) and duration of support (median 48.0 hours (IQR 26.8 to 77.5) vs 17.0 (14.0 to 37.0)) was lower in the PH group, with comparable MABPs.
Conclusion: A PH approach in preterm infants is feasible. It leads to comparable blood pressures with less inotrope administration. Though underpowered, we did not detect a major negative impact of PH on short-term or long-term outcomes.
Trial registration number: NCT01434251.
Keywords: Intensive Care Units; Neonatology; Neurology.
© Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
Competing interests: Medtronic Inc. provided three additional INVOS 5100c monitors for the duration of the trial but was not otherwise involved in the study.
Associated data
LinkOut - more resources
Full Text Sources
Medical